RT Journal Article
SR Electronic
T1 Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.122.264946
DO 10.2967/jnumed.122.264946
A1 Gudenkauf, Lisa M.
A1 Chavez, Melody
A1 Maconi, Melinda L.
A1 Geiss, Carley
A1 Seyedroudbari, Ameen
A1 Thin, Pan
A1 Hoogland, Aasha I.
A1 Nguyen, Kathleen
A1 Murthy, Vishnu
A1 Armstrong, Wesley R.
A1 Komrokji, Khaled
A1 Oswald, Laura B.
A1 Jim, Heather S.L.
A1 El-Haddad, Ghassan
A1 Fendler, Wolfgang Peter
A1 Herrmann, Ken
A1 Cella, David
A1 Czernin, Johannes
A1 Hofman, Michael S.
A1 Dicker, Adam P.
A1 Calais, Jeremie
A1 Tagawa, Scott T.
A1 Gonzalez, Brian D.
YR 2023
UL http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.abstract
AB The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the FACT-RNT with patient input. Results: This multi-step process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a new standardized tool to monitor relevant symptoms/toxicities in RNT trials and real-world settings.